OBJECTIVE: Most previous longitudinal studies demonstrating relationships between psychosocial variables and human immunodeficiency virus (HIV) disease progression utilized samples of gay men accrued before the era of highly active antiretroviral treatment (HAART), without including viral load (VL) as an indicator of disease progression or assessing the impact of medication adherence. This study sought to determine whether psychosocial variables would predict both CD4 and VL changes in a diverse sample assessed entirely during the era of HAART and accounting for adherence effects. METHODS: This longitudinal study assessed a multiethnic HIV+ sample (n = 177) of men and women in the midrange of illness (CD4 number between 150 and 500; no previous acquired immunodeficiency syndrome [AIDS]-defining symptom) every 6 months for 2 years. Hierarchical linear modeling was used to model change in CD4 and VL controlling for sociodemographics (age, gender, ethnicity, education) and medical variables (baseline CD4/VL, antiretroviral medications at each time point, adherence). RESULTS: Baseline depression, hopelessness, and education predicted the slope of CD4 and VL. Avoidant coping and life event stress predicted VL change. Cumulative variables produced stronger relationships (depression, avoidant coping, and hopelessness with CD4/VL slope and life events stress with VL slope). High cumulative depression and avoidant coping were associated with approximately twice the rate of decline in CD4 as low scorers and greater relative increases in VL. Social support was not significantly related to CD4 or VL slope. CONCLUSIONS: Psychosocial factors contribute significantly to the variance in HIV disease progression (assessed through CD4 number and VL) in a diverse sample, accounting for adherence and do so in the era of HAART.
OBJECTIVE: Most previous longitudinal studies demonstrating relationships between psychosocial variables and human immunodeficiency virus (HIV) disease progression utilized samples of gay men accrued before the era of highly active antiretroviral treatment (HAART), without including viral load (VL) as an indicator of disease progression or assessing the impact of medication adherence. This study sought to determine whether psychosocial variables would predict both CD4 and VL changes in a diverse sample assessed entirely during the era of HAART and accounting for adherence effects. METHODS: This longitudinal study assessed a multiethnic HIV+ sample (n = 177) of men and women in the midrange of illness (CD4 number between 150 and 500; no previous acquired immunodeficiency syndrome [AIDS]-defining symptom) every 6 months for 2 years. Hierarchical linear modeling was used to model change in CD4 and VL controlling for sociodemographics (age, gender, ethnicity, education) and medical variables (baseline CD4/VL, antiretroviral medications at each time point, adherence). RESULTS: Baseline depression, hopelessness, and education predicted the slope of CD4 and VL. Avoidant coping and life event stress predicted VL change. Cumulative variables produced stronger relationships (depression, avoidant coping, and hopelessness with CD4/VL slope and life events stress with VL slope). High cumulative depression and avoidant coping were associated with approximately twice the rate of decline in CD4 as low scorers and greater relative increases in VL. Social support was not significantly related to CD4 or VL slope. CONCLUSIONS:Psychosocial factors contribute significantly to the variance in HIV disease progression (assessed through CD4 number and VL) in a diverse sample, accounting for adherence and do so in the era of HAART.
Authors: Pamela H Mitchell; Lynda Powell; James Blumenthal; Jennifer Norten; Gail Ironson; Carol Rogers Pitula; Erika Sivarajan Froelicher; Susan Czajkowski; Marston Youngblood; Marc Huber; Lisa F Berkman Journal: J Cardiopulm Rehabil Date: 2003 Nov-Dec Impact factor: 2.081
Authors: J Leserman; E D Jackson; J M Petitto; R N Golden; S G Silva; D O Perkins; J Cai; J D Folds; D L Evans Journal: Psychosom Med Date: 1999 May-Jun Impact factor: 4.312
Authors: S W Cole; B D Naliboff; M E Kemeny; M P Griswold; J L Fahey; J A Zack Journal: Proc Natl Acad Sci U S A Date: 2001-10-23 Impact factor: 11.205
Authors: Melcior Riera; Laura de La Fuente Ld; Bartomeu Castanyer; Francesc Puigventós; Concepción Villalonga; M Angels Ribas; Antonio Pareja; Maria Leyes; Ana Salas Journal: Med Clin (Barc) Date: 2002-09-14 Impact factor: 1.725
Authors: M Reuel Friedman; Ron Stall; Anthony J Silvestre; Chongyi Wei; Steve Shoptaw; Amy Herrick; Pamela J Surkan; Linda Teplin; Michael W Plankey Journal: AIDS Date: 2015-06-01 Impact factor: 4.177
Authors: Allison J Applebaum; C Andres Bedoya; Ellen S Hendriksen; Jesse L Wilkinson; Steven A Safren; Conall O'Cleirigh Journal: J Assoc Nurses AIDS Care Date: 2014-11-10 Impact factor: 1.354
Authors: Angela M Bengtson; Brian W Pence; Bradley N Gaynes; E Byrd Quinlivan; Amy D Heine; Julie K OʼDonnell; Heidi M Crane; W Christopher Mathews; Richard D Moore; Daniel Westreich; Conall OʼCleirigh; Katerina Christopoulos; Matthew J Mimiaga; Michael J Mugavero Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: Siegfried Geyer; Dorothee Noeres; Mariya Mollova; Heike Sassmann; Alexandra Prochnow; Mechthild Neises Journal: Support Care Cancer Date: 2008-07-29 Impact factor: 3.603
Authors: Sara N Levintow; Brian W Pence; Tran Viet Ha; Nguyen Le Minh; Teerada Sripaipan; Carl A Latkin; Pham The Vu; Vu Minh Quan; Constantine Frangakis; Vivian F Go Journal: AIDS Behav Date: 2019-03
Authors: Ethan Moitra; Bradley J Anderson; Debra S Herman; Jumi Hayaki; Megan M Pinkston; H Nina Kim; Michael D Stein Journal: AIDS Care Date: 2020-02-25